Rheumatology Advance Access originally published online on March 22, 2005
Rheumatology 2005 44(5):677-680; doi:10.1093/rheumatology/keh610
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis
Divisions of Clinical Epidemiology, Montreal General Hospital and 1 Royal Victoria Hospital, McGill University Health Centre, Montreal, Canada.
Correspondence to: S. Suissa, Division of Clinical Epidemiology, Royal Victoria Hospital, 687 Pine Avenue West, Ross 4.29, Montreal, Québec, Canada, H3A 1A1. E-mail: samy.suissa{at}clinepi.mcgill.ca
Objective. To assess the risk of hospitalization for congestive heart failure (CHF) associated with the use of disease-modifying anti-rheumatic drugs (DMARDs) and other medications used in RA.
Methods. We used a case–control design nested within an administrative database cohort of patients with rheumatoid arthritis (RA) who were dispensed a DMARD between September 1998 and December 2001. Subjects identified with a prior history of CHF were excluded. For each hospitalized case of CHF identified during follow-up, 10 controls matched on age and time were randomly selected from the cohort. Conditional logistic regression was used to estimate the rate ratio (RR) of hospitalizations for CHF associated with the current use of specific drugs, adjusted for sex and co-morbidity.
Results. The cohort included 41 885 patients; 75% were women, with an average age at cohort entry of 51 yr. During follow-up, 520 hospitalizations for CHF occurred, for a rate of 10.1 per 1000 per year. The adjusted RR of CHF for current use of any DMARD was 0.7 (95% CI 0.6–0.9) relative to no current use. By DMARD category, there was evidence of a beneficial effect for both tumour necrosis factor-
antagonists (RR 0.5, 95% CI 0.2–0.9) and methotrexate monotherapy (RR 0.8, 95% CI 0.6–1.0). For non-DMARD medications, the rate of CHF was not clearly increased or decreased, except for COX-2 inhibitors. The data suggested an increased risk of CHF with rofecoxib (RR 1.3, 95% CI 1.0–3.1) and a decreased risk of CHF with celecoxib (RR 0.6, 95% CI 0.4, 1.0).
Conclusions. The use of DMARDs was associated with a reduction in the risk of hospitalizations for CHF in this RA cohort. The increased risk with rofecoxib alongside a decreased risk with celecoxib suggests the absence of a class effect with respect to COX-II inhibitors for some types of cardiovascular morbidity.
KEY WORDS: Congestive heart failure, DMARDs, Rheumatoid arthritis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. A Scott, G. H. Kingsley, and D. L Scott Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials Eur J Heart Fail, November 1, 2008; 10(11): 1102 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bernatsky, A. E. Clarke, and S. Suissa Hematologic Malignant Neoplasms After Drug Exposure in Rheumatoid Arthritis Arch Intern Med, February 25, 2008; 168(4): 378 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R Walker Glucocorticoids and Cardiovascular Disease Eur. J. Endocrinol., November 1, 2007; 157(5): 545 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Curtis, J. M. Kramer, C. Martin, K. G. Saag, N. Patkar, D. Shatin, M. Burgess, A. Xie, and M. M. Braun Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-{alpha} antagonists Rheumatology, November 1, 2007; 46(11): 1688 - 1693. [Abstract] [Full Text] [PDF]
|
|